Polymorphic Form III Crystallization for Alzheimer's Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly acetylcholinesterase inhibitors, are not effective for many patients and do not slow disease progression, highlighting a need for more effective symptomatic and disease-modifying therapies.
Innovation Solution
Development of polymorphic form III of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride, a 5-HT6 receptor antagonist, which is produced through specific crystallization processes in organic solvents at controlled temperatures, providing a thermodynamically stable form for improved biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors are used for Alzheimer's disease treatment, then symptomatic management is provided, but biological efficacy and disease progression slowing are insufficient
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing a new polymorphic form (Form III) of the 5-HT6 receptor antagonist compound. This polymorphic form exhibits different physical and chemical parameters compared to previously known forms, including enhanced thermodynamic stability, improved solubility characteristics, and optimized bioavailability. These parameter changes in the compound's physical state directly address the insufficient biological efficacy and disease progression slowing observed with conventional treatments.
Solution Approach 2:
The invention utilizes composite material principles by creating a pharmaceutical composition that combines the 5-HT6 receptor antagonist in its specific polymorphic Form III with appropriate excipients and formulation components. This composite approach enhances the overall therapeutic effect, improving both biological efficacy and the ability to slow disease progression while maintaining the desired symptomatic management benefits.
2Stability of the object's composition
If polymorphic form III is produced through specific crystallization processes, then thermodynamic stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs phase transition principles by utilizing controlled crystallization processes to transform the compound from less stable forms to the thermodynamically stable polymorphic Form III. The invention specifies particular crystallization conditions including temperature ranges, solvent systems, and cooling rates that facilitate this phase transition. By establishing standardized phase transition protocols, the method achieves enhanced thermodynamic stability while controlling manufacturing complexity through defined procedural parameters.
Solution Approach 2:
The invention applies parameter changes by optimizing specific crystallization parameters such as solvent composition, temperature profiles, pH levels, and addition rates to reliably produce polymorphic Form III. These controlled parameter changes during the crystallization process enable consistent formation of the desired stable polymorphic form while maintaining manufacturability through well-defined process conditions that can be scaled and standardized.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Polymorphic form III offers enhanced stability and biological efficacy as a potential adjunctive therapy to acetylcholinesterase treatments, potentially providing better management and slowing of Alzheimer's disease progression.
Implementation Method 1
capturing polymorphic form III of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride from a suspension of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine in an organic solvent selected from the list of acetonitrile, proprionitrile, acetone, methanol, ethanol, toluene and xylenes (ortho, meta or para) or a mixture thereof, at a temperature below 60°C
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a novel polymorphic form of N-[2-(6-fluoro-lH-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine hydrochloride.